BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19395997)

  • 21. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.
    Hess LM; Benham-Hutchins M; Herzog TJ; Hsu CH; Malone DC; Skrepnek GH; Slack MK; Alberts DS
    Int J Gynecol Cancer; 2007; 17(3):561-70. PubMed ID: 17504373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M; Reichman B; Hakes T; Jones W; Lewis JL; Rubin S; Almadrones L; Hoskins W
    J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M; Blessing JA; Major F; Manetta A
    Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
    Markman M; Bundy BN; Alberts DS; Fowler JM; Clark-Pearson DL; Carson LF; Wadler S; Sickel J
    J Clin Oncol; 2001 Feb; 19(4):1001-7. PubMed ID: 11181662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
    Bunting M; Chan W; Brand A; Blomfield P
    Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
    Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
    Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
    Hayashi H; Nishii H; Ueda K; Kunitou S; Wada S; Takanashi H; Kobayashi S; Yasuda M
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
    Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
    Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
    Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
    Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
    Howell SB; Kirmani S; McClay EF; Kim S; Braly P; Plaxe S
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):5-10. PubMed ID: 2003227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?
    Echarri Gonzalez MJ; Green R; Muggia FM
    Oncology (Williston Park); 2011 Feb; 25(2):156-65, 170. PubMed ID: 21456387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
    Ozols RF
    Cancer Invest; 2004; 22 Suppl 2():11-20. PubMed ID: 15573741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
    Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
    Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.